Ziphius Vaccines Announces Positive Preclinical data from its self-amplifying RNA Vaccine Platform

December 21, 2020 at 8:00 PM EST

Ziphius Vaccines, a self-amplifying RNA company developing transformative infectious disease vaccines, today announced promising results from its proprietary vaccine platform.

Ziphius’ proprietary sa-RNA platform is a highly relevant platform for producing vaccines. It allows to code for any antigen of interest as well as combining multiple antigens, resulting in a broad immune response. Our platform has the ability to replicate in the cell before transcription to an antigen, leading to an increased RNA expression in the cells and therefore active at a lower dose. Furthermore, the results show a low cytokine production, promising low inflammatory side effects.

Compared to other COVID-19 mRNA vaccines, ZIP-1642, Ziphius’ next generation SARS-CoV-2 vaccine, induced higher and more potent neutralizing antibodies. This was shown by a longer duration of expression and higher potency of protection.

“We are extremely pleased with this validation of our sa-RNA platform and look forward to further developing ZIP-1642 into the clinic. While current SARS-CoV-2 vaccines report 95% efficacy, our technology has the potential to add the remaining 5% and remain highly relevant to any future coronavirus mutations.” said Chris Cardon, CEO at Ziphius Vaccines. “We look forward to leverage our platform onto our other 9 vaccine candidates already in the pipeline.”


Phase 1/2 clinical trials are anticipated to begin in the fourth quarter of 2021.

About ZIP-1642

ZIP-1642 consists of a combination of mRNA molecules, encoding multiple SARS-CoV-2 antigens, such as a form of the Spike (S) protein, which is an essential protein for host cell infection and has been evaluated as a vaccine antigen for multiple other corona viruses. The vaccine consists of an mRNA-based technology, the platform has previously been used for the development of another vaccine. ​COVID-19 is caused by SARS-CoV-2, which belongs to a group of viruses called coronaviruses that attack the respiratory system. 

About Ziphius Vaccines

Ziphius Vaccines NV is a self-amplifying RNA company developing transformative infectious disease vaccines based on messenger RNA (mRNA), in order to create a new generation of transformative medicines for patients. Ziphius Vaccines is developing a portfolio of sa-RNA vaccines and therapeutics. To date, the Company has a portfolio of 10 next generation vaccine candidates targeting a wide range of infectious diseases.

Headquartered in Oostkamp, Belgium, Ziphius Vaccines currently has strategic partnerships with experienced executives in the pharmaceutical industry that bring over 100 years of combined experience in drug development.